A systematic review of the efficacy and safety of desipramine for treating ADHD

Current Drug Safety

Volumn 8, Issue 3, 2013, Pages 169-174

  Ghanizadeh, Ahmad ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adolescents; Antidepressive agents; Attention deficit hyperactivity disorder; Children; Desipramine; Therapeutics; Tricyclic

Indexed keywords

DESIPRAMINE;

ADOLESCENCE; APPETITE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL (TOPIC); DATA BASE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; XEROSTOMIA;

ADOLESCENT; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CLINICAL TRIALS AS TOPIC; DESIPRAMINE; HUMANS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84882764722     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748863113089990029     Document Type: Review

References (93)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV [Internet]. 4th ed. Washington (DC): American Psychiatric Association; 1994; http://www.psychiatryonline.com/DSMPDF/dsm-iv.pdf
2. Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. Postgrad Med 2010; 122: 5, 69-77.
3. Childress AC, Berry SA. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. Drugs, 2012; 72(3): 309-325.
4. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Adv Ther 2009; 26(2): 170-184.
5. Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ. Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 2008; 95(1-2): 140-146.
6. Ghanizadeh A. Psychiatric comorbidity differences in clinic-referred children and adolescents with ADHD according to the subtypes and gender. J Child Neurol 2009; 24(6): 679-684.
7. Ghanizadeh A, Mohammadi MR, Moini R. Comorbidity of psychiatric disorders and parental psychiatric disorders in a sample of Iranian children with ADHD. J Atten Disord 2008; 12(2): 149-155.
8. Turgay A. Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD). Essent Psychopharmacol 2005, 6(5), 277-290.
9. Greenhill L, Beyer DH., Finkleson J, et al. Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder. J Atten Disord 2002; 6 Suppl 1, S89-s100.
10. Engert V, Pruessner JC. Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Curr Neuropharmacol 2008; 6(4): 322-328.
11. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006; 60(10): 1111-1120.
12. Barkley RA, Grodzinsky G, DuPaul GJ. Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report. J Abnorm Child Psychol 1992; 20(2): 163-188.
13. Cottingham C, Jones A, Wang Q. Desipramine selectively potentiates norepinephrine-elicited ERK1/2 activation through the alpha(2A) adrenergic receptor. Biochem Biophys Res Commun 2012; 420(1):161-165.
14. Moungnoi P, Maipang P. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. J Med Assoc Thai 2011; 94(Suppl 3): S158-s163.
15. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47(9): 994-1009.
16. Spencer T, Biederman J, Wright V, Danon M. Growth deficits in children treated with desipramine: a controlled study. J Am Acad Child Adolesc Psychiatry 1992; 31(2): 235-243.
17. Gobshtis N, Ben-Shabat S, Fride E. Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness. Eur J Pharmacol 2007; 554(2-3): 155-163.
18. Ciraulo DA, Barnhill JG, Jaffe JH. Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 1988; 43(5): 509-518.
19. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20(8): 533-559.
20. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151(6): 737-748.
21. Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV. Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 2004; 14(2): 185-194.
22. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48(9); 884-893.
23. Bondi CO, Jett JD, Morilak DA. Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated by alpha1-adrenergic receptors in medial prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(6): 913-923.
24. Seu E, Jentsch JD. Effect of acute and repeated treatment with desipramine or methylphenidate on serial reversal learning in rats. Neuropharmacology 2009; 57(7-8): 665-672.
25. Rapport MD, Carlson GA, Kelly KL, Pataki C. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993; 32(2): 333-342.
26. Bizot JC, David S, Trovero F. Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure. Neurosci Lett 2011; 489(1): 20-24.
27. Orito K, Morishima A, Ogawa, T, et al. Characteristic behavioral anomalies in rats prenatally exposed to 5-bromo-2'-deoxyuridine. Int J Dev Neurosci 2009; 27(1): 81-86.
28. Tilley MR, Gu HH. The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther 2008; 327(2): 554-560.
29. Ghanizadeh, A. Factor analysis on ADHD and autism spectrum disorder DSM-IV-derived items shows lack of overlap. Eur Child Adolesc Psychiatry 2010; 19(10): 797-798.
30. Ghanizadeh, A. Co-morbidity and factor analysis on attention deficit hyperactivity disorder and autism spectrum disorder DSM-IV-derived items. Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences 2012; 17(4): 368-372.
31. Ghanizadeh A. Atomoxetine for Treating ADHD Symptoms in Autism: A Systematic Review. J Atten Disord, 2012.
32. Ghanizadeh A, Berk M. Zinc for treating of children and adolescents with attention-deficit hyperactivity disorder: a systematic review of randomized controlled clinical trials. European J Clinic Nutr 2013; 67(1): 122-124.
33. Ghanizadeh A. Systematic review of magnesium for treating ADHD. Arch Iran Med 2013; 16(7): 412-417.
34. Ghanizadeh A., Freeman RD, Berk M. Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: a systematic review of non-controlled and controlled trials. Rev Recent Clinic Trials 2013; 8(1): 2-8.
35. Ghanizadeh A, Haghighat R. Nortriptyline for treating enuresis in ADHD--a randomized double-blind controlled clinical trial. Pediatr Nephrol, 2012; 27(11): 2091-2097.
36. Amitai Y, Frischer H. Excess fatality from desipramine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45(1): 54-60.
37. Alderton HR. Tricyclic medication in children and the QT interval: case report and discussion. Can J Psychiatry 1995; 40(6): 325-329.
38. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32(4): 792-797.
39. Amitai Y, Frischer H. Excess fatality from desipramine and dosage recommendations. Ther Drug Monit 2004; 26(5); 468-473.
40. Biederman J, Baldessarini RJ, Goldblatt A, Lapey KA, Doyle A, Hesslein, PS. A naturalistic study of 24-hour electrocardiographic recordings and echocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32(4): 805-813.
41. Schroeder JS, Mullin AV, Elliott GR, et al. Cardiovascular effects of desipramine in children. J Am Acad Child Adolesc Psychiatry 1989; 28(3): 376-379.
42. Walsh BT, Giardina EG, Sloan RP, Greenhill L, Goldfein J. Effects of desipramine on autonomic control of the heart. J Am Acad Child Adolesc Psychiatry 1994; 33(2): 191-197.
43. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993; 32(4): 798-804.
44. Galanter CA, Bilich C, Walsh, BT. Side effects of desipramine and age. J Child Adolesc Psychopharmacol 2002; 12(2): 137-145.
45. Cohen LG, Biederman J, Wilens TE, et al. Desipramine clearance in children and adolescents: absence of effect of development and gender. J Am Acad Child Adolesc Psychiatry 1999; 38(1): 79-85.
46. Karakaya I, Aydogan M, Coskun A, Gokalp AS. Acrocyanosis as a side effect of tricyclic antidepressants: a case report. Turk J Pediatr 2003; 45(2): 155-157.
47. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.
48. Higgins JPT, Green S. The Cochrane Collaboration, 2008.
49. Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2002; 59(7): 649-656.
50. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989; 28(5): 777-784.
51. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36(7); 980-988.
52. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A. A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 1989; 28(6): 903-911.
53. Biederman J, Baldessarini RJ, Wright V, Keenan K, Faraone S. A double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response. J Am Acad Child Adolesc Psychiatry 1993; 32(1): 199-204.
54. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995; 95(1): 74-81.
55. Kutcher S, Boulos C, Ward B, et al. Response to desipramine treatment in adolescent depression: a fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 1994; 33(5); 686-694.
56. Johnson A, Giuffre RM, O'Malley K. ECG changes in pediatric patients on tricyclic antidepressants, desipramine, and imipramine. Can J Psychiatry 1996; 41(2); 102-106.
57. Popper CW. Antidepressants in the treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 1997; 58(Suppl 14): 14-29.
58. Bond DJ, Hadjipavlou G, Lam RW, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention deficit/hyperactivity disorder. Ann Clin Psychiatry 2012; 24(1): 23-37.
59. Spencer TJ. Treatment of adult ADHD and comorbid depression. CNS Spectr 2008; 13(5 Suppl 8): 14-16.
60. Davidson MA. ADHD in adults: a review of the literature. J Atten Disord 2008; 11(6): 628-641.
61. Slatkoff J, Greenfield B. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults. Expert Opin Investig Drugs 2006; 15(6): 649-667.
62. Maidment ID. The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol 2003; 17(3): 332-336.
63. Faraone SV, Biederman J, Spencer TJ, Wilens TE. The drug-placebo response curve: a new method for assessing drug effects in clinical trials. J Clin Psychopharmacol 2000; 20(6): 673-679.
64. Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract 1999; 48(1): 15-20.
65. Spencer T, Biederman, J, Wilens TE, Faraone SV. Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998; 59(Suppl 7): 59-68.
66. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153(9): 1147-1153.
67. Wilens TE, Biederman J, Mick E, Spencer, TJ. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995; 183(1): 48-50.
68. Magee R, Maier D, Reesal RT. Adult attention deficit hyperactivity disorder and desipramine. Can J Psychiatry 1992; 37(2): 148-149.
69. Seu E, Lang A, Rivera RJ, Jentsch JD. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys. Psychopharmacology (Berl) 2009; 202(1-3): 505-519.
70. Kanbayashi Y. [Attention deficit/hyperactivity disorder]. Ryoikibetsu Shokogun Shirizu, 2003; 40: 5-9.
71. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1991; 30(1): 104-108.
72. Hoge SK, Biederman J. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 1986; 47(9): 478-479.
73. Gualtieri CT, Keenan PA, Chandler M. Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder. J Clin Psychopharmacol 1991; 11(3): 155-159.
74. Riddle MA, Hardin MT, Cho SC, Woolston JL, Leckman JF. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1988; 27(6): 811-814.
75. Biederman J, Gastfriend DR, Jellinek MS. Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 1986; 6(6): 359-363.
76. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of adolescents with attention deficit disorder. Am J Psychiatry 1984; 141(7): 906-908.
77. Colson ER. Medication for children with attention disorders. Pediatrics 1997; 99(6): 922-923.
78. Pringsheim T, Steeves T. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011; 4: CD007990.
79. Turgay A, Ansari R. Major Depression with ADHD: In Children and Adolescents. Psychiatry (Edgmont) 2006; 3(4): 20-32.
80. Rains A, Scahill L, Hamrin V. Nonstimulant edications for the treatment of ADHD. J Child Adolesc Psychiatr Nurs 2006; 19(1):44-47.
81. Himpel S, Banaschewski T, Heise CA, Rothenberger A. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder. Expert Opin Drug Saf 2005; 4(2): 311-321.
82. Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care 2004; 10(4 Suppl): S117-124.
83. Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med 2002; 13(3): 599-624.
84. Shaywitz BA, Fletcher JM, Shaywitz SE. Attention Deficit Hyperactivity Disorder. Curr Treat Options Neurol 2001; 3(3): 229-236.
85. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000; 9(3): 605-646.
86. Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999; 11: 1-341.
87. Varley CK. A review of studies of drug treatment efficacy for attention deficit disorder with hyperactivity in adolescents. Psychopharmacol Bull 1985; 21(2): 216-221.
88. Overtoom CC, Verbaten MN, Kemner C, et al. Effects of methylphenidate, desipramine, and L-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder. Behav Brain Res 2003; 145(1-2): 7-15.
89. Spencer T, Biederman J, Kerman K, Steingard R, Wilens, T. Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32(2): 354-360.
90. Linet LS. Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 1987; 48(11): 456.
91. Donnelly M, Zametkin AJ, Rapoport JL, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 1986; 39(1): 72-81.
92. Gastfriend DR, Biederman J, Jellinek MS. Desipramine in the treatment of attention deficit disorder in adolescents. Psychopharmacol Bull 1985; 21(1): 144-145.
93. Pataki CS, Carlson GA, Kelly KL, Rapport MD, Biancaniello TM. Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 1993; 32(5): 1065-1072.